Bristol Acknowledges Medicaid Rebate Reporting Errors
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will ask CMS to review proposed changes to its price and rebate calculation methodology. Bristol says “errors” are not material, but acknowledges that CMS may request more changes. List of pending investigations against the company continues to expand.
You may also be interested in...
Bristol Agrees To One-Month Inventory Limit Under SEC Settlement
Settlement marks first definition of "normal" inventory levels for pharmaceutical industry. Bristol agrees to $150 mil. civil penalty to resolve investigation into "channel stuffing" during 2000-2001.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.